← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › CD22 (Clusters of Differentiation 22) inhibitors
moxetumomab pasudotox
L01FB02
Forms & Strengths
- Solution for infusion 1mg/mL
Adult Dosing
- Dose regimen: 40mcg/kg over 30 minutes on days 1, 3, and 5 of a 28-day cycle
- Dose adjustments: for adverse reactions
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
Indications
- Treatment of relapsed or refractory hairy cell leukemia
Mechanism of Action
- Immunotoxin targeting CD22 on malignant cells
- MoAb: moxetumomab, toxin: PE38
Contraindications
- Hypersensitivity to moxetumomab pasudotox or any of its components
Adverse Reactions
- Capillary leak syndrome
- Hemolytic uremic syndrome
- Infusion-related reactions
- Myelosuppression
Drug Interactions
- Concomitant use with other antineoplastic agents
Curated Content: Needs Vetting Before Put to Clinical Use